These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10893958)

  • 1. [Controlled tapering of medication. What do structured treatment withdrawal achieve?].
    MMW Fortschr Med; 2000; 142(3 Suppl):25-6. PubMed ID: 10893958
    [No Abstract]   [Full Text] [Related]  

  • 2. Fact sheet on structured treatment interruption.
    Res Initiat Treat Action; 2003; 9(2):20-1. PubMed ID: 14989203
    [No Abstract]   [Full Text] [Related]  

  • 3. [Quality of life as the focus of modern anti-HIV treatment. More compact regimens for therapy success].
    MMW Fortschr Med; 2001 Sep; 143(35-36):58-9. PubMed ID: 11584536
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy planning. It depends on the proper administration series].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():82-5. PubMed ID: 10863322
    [No Abstract]   [Full Text] [Related]  

  • 5. [HIV management requires strategic planning. Optimal sequencing of protease inhibitors].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():21-4. PubMed ID: 11373770
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effective, safe and simple. The future means "once daily"].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():40-4. PubMed ID: 12043073
    [No Abstract]   [Full Text] [Related]  

  • 7. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective].
    Wepner U
    MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085
    [No Abstract]   [Full Text] [Related]  

  • 8. [Structured interruptions in antiretroviral treatment: a new therapeutic strategy?].
    García F
    Enferm Infecc Microbiol Clin; 2002 Oct; 20(8):373-5. PubMed ID: 12372231
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiviral adherence dilemmas.
    Roland ME
    Focus; 1998 Feb; 13(3):1-4. PubMed ID: 11365167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who gets treatment and...side effects.
    TreatmentUpdate; 2002 Dec; 14(9):2-3. PubMed ID: 12593382
    [No Abstract]   [Full Text] [Related]  

  • 11. [Non-nucleoside reverse transcriptase inhibitors. First line therapy].
    MMW Fortschr Med; 2000; 142(3 Suppl):34-5. PubMed ID: 10893964
    [No Abstract]   [Full Text] [Related]  

  • 12. [Interview with Prof. Reinhold E. Schmidt. Important selection criteria: tolerance and simplicity]].
    Schmidt RE
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():84-5. PubMed ID: 16385889
    [No Abstract]   [Full Text] [Related]  

  • 13. Millennial heresy.
    Proj Inf Perspect; 2000 Mar; (29):1-4. PubMed ID: 12769048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects and complications. Swedes compare treatment switching with interruption.
    TreatmentUpdate; 2005 Dec; 17(7):11. PubMed ID: 17225325
    [No Abstract]   [Full Text] [Related]  

  • 15. [Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():18-21. PubMed ID: 11373769
    [No Abstract]   [Full Text] [Related]  

  • 16. Review of recent guidelines for antiretroviral treatment of HIV-infected children.
    Oleske JM
    Top HIV Med; 2003; 11(6):180-4. PubMed ID: 14724326
    [No Abstract]   [Full Text] [Related]  

  • 17. New developments in STIs and SIT.
    Proj Inf Perspect; 2000 Oct; (31):5. PubMed ID: 12171020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy demonstrated for once-daily regimen.
    AIDS Patient Care STDS; 2003 Nov; 17(11):603. PubMed ID: 14748355
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-HIV agents. Treatment interruption surprisingly does not reduce heart disease risk.
    TreatmentUpdate; 2009 Jan; 21(1):7-9. PubMed ID: 19248286
    [No Abstract]   [Full Text] [Related]  

  • 20. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions.
    Eron JJ
    J Infect Dis; 2008 May; 197 Suppl 3():S261-71. PubMed ID: 18447612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.